Photo of Andrew Wei

View Scopus Profile

Andrew Wei

Dr

 https://orcid.org/0000-0002-7514-3298
20082024
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Dr Andrew Wei is a Victorian Cancer Agency Research Fellow and Haematologist at the Alfred Hospital. Andrew conducts clinical and translational AML research through dual appointments at the Alfred Hospital and Monash University.

After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, he joined the Alfred Hospital in 2008 to develop the AML research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator. His doctoral research studies contributed to discoveries elucidating the functional interaction between Bcl-2 family members (Molecular Cell 2005;17(3):393-403), the role of Mcl-1 in cancer susceptibility to ABT-737 (Cancer Cell. 2006;10(5):389-99) and the pro-survival function of the EBV Bcl-2 homologue BHRF-1 (PLoS Pathogens 2010;6[12]).

Dr Wei is an executive member of the ALLG Scientific Advisory Committee, a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia and Head of Leukaemia Research at the Alfred hospital. He sits on the International Steering Committee for Celgene providing expert advice on AML. To enhance translational research, Dr Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.

Related Links:

Research interests

Dr. Wei's research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Wei's laboratory seeks to identify new therapeutic targets in leukaemia.

Projects:

  1. Targetting 'survival kinases' in leukemic stem and progenitor cells
  2. The role of inositol phosphatases in regulating normal and malignant hemopoiesis
  3. Human models of AML

Monash teaching commitment

2007 - Present : Adjunct senior lecturer

Clinical activities

Investigator initiated AML trail funding:

  • Phase 1 study of RAD001 and low dose ara-C for elderly AML
  • Phase 1 study of azacitidine and lenalidomide as maintenance therapy in AML
  • Phase 1 study of azacitidine and everolimus in relapsed AML
  • Phase 1 multicentre ALLG study of lenalidomide maintenance therapy in AML
  • Phase 2 randomised controlled multicentre ALLG study of Sorafenib in FLT3-ITD AML 
  • Phase 2 randomised multicentre ALLG study of high-dose lenalidomide and azacitidine and depsipeptide in relapsed AML

Cooperative Group Studies Local Site PI:

  • Phase 3 study: ALLG AML M12 study
  • Phase 2 study: ALLG APML M4 study
  • Phase 2/3: UK MRC16 AML study

Company sponsored studies as local site PI:

  • Phase 2 study: CEP-701 in relapsed AML
  • Phase 2 study: AS1411 in relapsed AML
  • Phase 2 study: Midostaurin in systemic mastocytosis
  • Phase 2/3 study: AZD1152 in older AML
  • Phase 3 study: PKC412 in AML
  • Phase 3 study: Amonafide in secondary AML
  • Phase 3 study: Elacytarabine in relapsed AML
  • Phase 3: Voreloxin in relapsed AML
  • Phase 1: KB004 in advanced haematological malignancies
  • Phase 1: Meisoindigo in AML unfit for chemotherapy

Keywords

  • Acute myeloid leukaemia
  • Azacytidine
  • BH3
  • Bcl-2
  • Lenalidomide
  • Leukaemia Foundation
  • Leukemia
  • Lymphoma
  • Mcl-1
  • Relapse and refractory
  • Research Fellow
  • Victorian Cancer Agency
  • clinical AML
  • leukaemic stem cells
  • translational AML

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2009 2024

A phase 1b, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).

Wei, A. & Kennedy, N.

23/05/19 → 23/05/24

Project: Research

Transforming the treatment landscape in elderly Acute Myeloid Leukaemia (AML)

Wei, A., Bohlander, S., Reynolds, J. & Levis, M.

1/05/19 → 31/12/22

Project: Research

Novel Venetoclax Combinations To Improve Outcomes In Unfit Older Patients With Acute Myeloid Leukaemia

Wei, A., Reynolds, J., Ritchie, D., Ananda-Rajah, M., Liew, D. & Ivey, A.

1/04/19 → 31/03/24

Project: Research

Tisagenlecleucel versus blinatumomab or inotuzumab for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A randomized, open-label, multicenter, phase III trial (OBERON).

Wei, A. & Kennedy, N.

28/03/19 → 31/12/24

Project: Research

Integrated Management of Post Remission Leukaemia to Optimise longevity and Enhance Quality of Life

Wei, A., Fleming, S. A. & Rady, K.

14/03/19 → 30/05/22

Project: Research

Research Output 2008 2019

Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T. C., Tiong, I. S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F. & 7 othersSegal, D., Huang, D., Roberts, A. W., Maragno, A. L., Lessene, G., Geneste, O. & Wei, A. H., 1 Apr 2019, In : Leukemia. 33, a, p. 905-917 13 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

Genomic subtyping and therapeutic targeting of acute erythroleukemia

Iacobucci, I., Wen, J., Meggendorfer, M., Choi, J. K., Shi, L., Pounds, S. B., Carmichael, C. L., Masih, K. E., Morris, S. M., Lindsley, R. C., Janke, L. J., Alexander, T. B., Song, G., Qu, C., Li, Y., Payne-Turner, D., Tomizawa, D., Kiyokawa, N., Valentine, M., Valentine, V. & 28 othersBasso, G., Locatelli, F., Enemark, E. J., Kham, S. K. Y., Yeoh, A. E. J., Ma, X., Zhou, X., Sioson, E., Rusch, M., Ries, R. E., Stieglitz, E., Hunger, S. P., Wei, A. H., To, L. B., Lewis, I. D., D’Andrea, R. J., Kile, B. T., Brown, A. L., Scott, H. S., Hahn, C. N., Marlton, P., Pei, D., Cheng, C., Loh, M. L., Ebert, B. L., Meshinchi, S., Haferlach, T. & Mullighan, C. G., Apr 2019, In : Nature Genetics. 51, 4, p. 694-704 11 p.

Research output: Contribution to journal › Article › Research › peer-review

AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies

Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., Cardozo, M., Houze, J., Li, Y., Lucas, B., Paras, N. A., Wang, X., Taygerly, J. P., Vimolratana, M., Zancanella, M., Zhu, L. & 18 othersCajulis, E., Osgood, T., Sun, J., Damon, L., Egan, R. K., Greninger, P., McClanaghan, J. D., Gong, J., Moujalled, D., Pomilio, G., Beltran, P., Benes, C. H., Roberts, A. W., Huang, D. C., Wei, A., Canon, J., Coxon, A. & Hughes, P. E., 1 Dec 2018, In : Cancer Discovery. 8, 12, p. 1582-1597 16 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

Tiong, I. S., Reynolds, J., Bradstock, K. F., Seymour, J. F., Wei, A. H. & on behalf of the Australasian Leukaemia & Lymphoma Group, 22 Aug 2018, In : Blood Cancer Journal. 8, 9, 5 p., 84.

Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

Teh, T. C., Nguyen, N. Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., Thompson, E., Ekert, P. G., Lessene, G., Glaser, S. P., Huang, D. C. S., Roberts, A. W., Guthridge, M. A. & Wei, A. H., 1 Feb 2018, In : Leukemia. 32, 2, p. 303-312 10 p.

Research output: Contribution to journal › Article › Research › peer-review

Prizes

2003: Albert Baikie Award, Best Oral Abstract Presentation, Haematology Society of Australia

Andrew Wei (Recipient), 2004

Prize: Prize (including medals and awards)

2003: Young Investigator Award, Best Oral Abstract Presentation, Annual Scientific Meeting, Hobart

Andrew Wei (Recipient), 2003

Prize: Prize (including medals and awards)

2004: New Investigator Award, Best Oral Abstract, Annual Scientific Meeting, Canberra

Andrew Wei (Recipient), 2004

Prize: Prize (including medals and awards)

Activities 2012 2012

  • 8 Membership of an advisory panel/policy group/ board

AMERICAN SOCIETY OF HAEMATOLOGY (External organisation)

Andrew Wei (Member)
1 Jan 2012

Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board

HAEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND (External organisation)

Andrew Wei (Member)
1 Jan 2012

Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board

The Royal Australasian College of Physicians (External organisation)

Andrew Wei (Member)
1 Jan 2012

Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board

AUSTRALASIAN SOCIETY FOR BLOOD TRANSFUSION (External organisation)

Andrew Wei (Member)
1 Jan 2012

Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board

AUSTRALIAN SOCIETY OF THROMBOSIS AND HAEMOSTASIS (External organisation)

Andrew Wei (Member)
1 Jan 2012

Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board